Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|May 12, 2022
Natoli Announces Tablet Press & Tooling Training Schedule at Company Headquarters
Author(s)Pharmaceutical Technology Editors
The “Tablet Press & Tooling: Applied Learning Experience” session will be held from June 14-16 at Natoli’s global headquarters in St. Charles, Mo.
Advertisement
Natoli announced the date and location for its latest training workshop on May 9, 2022. The “Tablet Press & Tooling: Applied Learning Experience” session will be from June 14-16 at the company's global headquarters in St. Charles, Mo.
Natoli invites supervisors, quality assurance and quality control personnel, and maintenance technicians at any stage to attend the session. The course, which is offered several times each year, will cover:
- Assembly and disassembly of all main components of a rotary tablet press
- Mechanics of press failures and cam wear
- Relationships among maintenance, inspections, operations, and troubleshooting
“Operators’ jobs are hands-on, so their training should be, too,” said Dale Natoli, president and CEO, Natoli Engineering. "The heavy focus on hands-on experience and classroom instruction provides the perfect balance to show attendees how tablet presses and tooling work in theory and in practice."
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement